Novartis AG (NVS)

Novartis AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	14,850	6,955	24,021	8,072	11,732
Depreciation & Amortization	10,369	10,631	-6,430	9,881	9,122
Other Operating Activities	-10,761	-3,350	-2,520	-4,303	-7,229
Operating Cash Flow	14,458	14,236	15,071	13,650	13,625
Operating Cash Flow Growth	1.56%	-5.54%	10.41%	0.18%	-4.53%
Capital Expenditures	-823	-758	-855	-1,187	-522
Acquisitions	-3,569	-864	20,464	-9,964	-3,766
Change in Investments	10,849	4,680	-13,853	-915	3,183
Other Investing Activities	-861	-1,590	-1,548	-1,116	-1,121
Investing Cash Flow	5,596	1,468	4,208	-13,182	-2,226
Dividends Paid	-7,255	-7,506	-7,368	-6,987	-6,645
Share Issuance / Repurchase	-8,566	-10,552	-3,004	-2,094	-5,332
Debt Issued / Paid	-1,935	-2,585	-5,987	7,072	-4,957
Other Financing Activities	3,478	81	95	-199	3,307
Financing Cash Flow	-14,278	-20,562	-16,264	-2,208	-13,627
Net Cash Flow	5,876	-4,890	2,749	-1,454	-2,159
Free Cash Flow	13,635	13,478	14,216	12,463	13,103
Free Cash Flow Growth	1.16%	-5.19%	14.07%	-4.88%	-0.13%
Free Cash Flow Margin	29.22%	31.01%	32.33%	24.98%	26.92%
Free Cash Flow Per Share	6.65	6.31	6.36	5.47	5.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).